Blindness News and Research

RSS

AAO-MEACO Meeting highlights data on glaucoma risk in people with migraine, innovative uses of digital technology

Data on glaucoma risk in people with migraine and on innovative uses of mobile, digital technology are featured in today's Scientific Program, to be presented at the 2010 American Academy of Ophthalmology (AAO) - Middle East-Africa Council of Ophthalmology (MEACO) Joint Meeting.

18 Oct 2010

Researchers report progress on two eye disease challenges at AAO-MEACO 2010 Joint Meeting

At the American Academy of Ophthalmology (AAO) Middle East-Africa Council of Ophthalmology (MEACO) Joint Meeting today, researchers report progress on two top eye disease challenges treating advanced "dry" age-related macular degeneration, and preventing blindness in people with diabetes.

18 Oct 2010

FDA approves BOTOX as prophylactic treatment for Chronic Migraine

Allergan, Inc. today announced the United States Food and Drug Administration (FDA) has approved BOTOX(onabotulinumtoxinA) for the prophylactic (preventive) treatment of headaches in adults with Chronic Migraine.

18 Oct 2010

New implantable pressure sensor for patients with cataract and glaucoma

AcuMEMS, Inc. today announced the development of a new sensor for wireless intraocular pressure (IOP) monitoring of patients with co-incident cataract and glaucoma. Successful animal studies confirm the precise delivery of the implantable pressure sensor into the eye where synthetic intraocular lenses (IOL) are inserted for cataract treatment.

15 Oct 2010

Alimera Sciences obtains $32.5M senior secured credit facility

Alimera Sciences, Inc. announced today that it has obtained a $32.5 million senior secured credit facility to help fund its working capital requirements. The credit facility consists of a $20 million revolving line of credit provided by Silicon Valley Bank and a $12.5 million term loan provided by MidCap Financial, LLC and Silicon Valley Bank.

15 Oct 2010

Issuing first report on NTDS, WHO aims for 'complete control' by 2015

The WHO said on Thursday that it was aiming for 'complete control' by 2015 of tropical diseases that affect one billion impoverished people and kill an estimated 534,000 people each year, Agence France-Presse reports.

15 Oct 2010

Bayhill to present BHT-3009 Phase 2 clinical trial data at European Committee Congress

Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company leveraging its proprietary BHT-DNA platform to develop targeted autoimmune disease treatments, today announced that it will present at the 26th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis and 15th Annual Conference of Rehabilitation in MS in Gothenburg, Sweden, data from its concluded Phase 2 clinical trial showing that baseline blood plasma anti-MBP (myelin basic protein) profiles identify responders to BHT-3009 treatment.

14 Oct 2010

Bariatric surgery reduces healthcare costs for morbidly obese diabetics

New data presented today at Obesity 2010, the 28th annual scientific meeting of The Obesity Society, find that bariatric surgery is associated with reduced healthcare costs for diabetes patients who are morbidly obese.

13 Oct 2010

Ocular Therapeutix completes Proof of Principle clinical study with moxifloxacin punctum plug

Ocular Therapeutix, Inc. announced today the completion of a successful Proof of Principle clinical study with their novel sustained drug delivery moxifloxacin punctum plug.

13 Oct 2010

Alimera to present Iluvien Phase 3 clinical trial data at AAO annual meeting

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that data from its Phase 3 (FAME) clinical trials for Iluvien will be presented this month at the annual meeting of the American Academy of Ophthalmology (AAO) in Chicago.

12 Oct 2010

Medicare recipients receiving treatment for retinal condition increases with shifts in procedure

The number of Medicare recipients undergoing treatment for retinal conditions nearly doubled between 1997 and 2007, with significant shifts in the types of procedures most commonly performed, according to a report in the October issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

12 Oct 2010

Biologists recommend virtual institute for RNA research

A Europe-wide network of labs focusing on RNA research is needed to make the most of RNA's high potential for treating a wide range of diseases. The recommendation for this virtual research institute comes from a panel of biologists at the European Science Foundation in a report published today, 'RNA World: a new frontier in biomedical research'.

12 Oct 2010

Attorney Keith Jensen announces $3.78 million settlement with Pfizer on TEN case

Attorney Keith Jensen of the Fort Worth, Texas-based law firm of Jensen, Belew & Gonzalez is announcing a $3.78 million settlement with pharmaceutical manufacturer Pfizer Inc. on behalf of the family of a nine-year-old New York girl who died in June 2004 as the result of a drug-induced disease known as Stevens Johnson Syndrome, which caused all of her skin to peel off.

11 Oct 2010

Cell Cure, Teva Pharmaceutical enter license option agreement for OpRegen product

BioTime, Inc., Cell Cure Neurosciences Ltd., and Hadasit Bio-Holdings Ltd. jointly announced today that Cell Cure and Teva Pharmaceutical Industries Ltd. have entered into an exclusive license option agreement to develop and commercialize Cell Cure's OpRegen product for the treatment of age-related macular degeneration (AMD).

11 Oct 2010

Scientists develop first screening method to identify river blindness disease

Scientists from The Scripps Research Institute have developed the first screening method that rapidly identifies individuals with active river blindness, a parasitic disease that afflicts an estimated 37 million people. The test could change the current strategy of mass treatment in areas where river blindness, also known as onchocerciasis, is suspected.

7 Oct 2010

Depressed pregnant women at increased risk of delivering preterm birth and low-birth weight infants

Clinical depression puts pregnant women at increased risk of delivering prematurely and of giving birth to below-normal weight infants, according to a report published Oct. 4 in the Archives of General Psychiatry.

5 Oct 2010

Enzo commences clinical trial of Optiquel for chronic non-infectious uveitis

Enzo Biochem, Inc., announced today that, following filing of a investigational new drug (IND) application with the FDA, its Enzo Therapeutics division is commencing a clinical trial of Optiquel™ , the Company's proprietary oral therapeutic for chronic non-infectious uveitis. The trial is designed as a randomized, double-masked, placebo-controlled study with a long-term follow-up and is being conducted by the National Institute of Health's National Eye Institute (NEI).

4 Oct 2010

Cost-effective ways for early detection of 'lazy eye'

Amblyopia, known as "lazy eye," is a major cause of vision problems in children and a common cause of blindness in people aged 20 to 70 in developed countries. In amblyopia the person's stronger eye is favored and his/her weaker eye gradually loses visual power as a result. When the condition is detected and treated before age 7, more than 75 percent of children achieve 20/30 vision or better, the Amblyopia Treatment Study reports.

4 Oct 2010

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck today announced that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, will be presented in oral plenary sessions at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place from Oct. 29 through Nov. 2 in Boston. Results for boceprevir in response-guided therapy strategies, which evaluated treatment durations shorter than current standard therapy, will be presented during the meeting.

4 Oct 2010

NIH to award $64M under Transformative Research Projects program

The National Institutes of Health will award up to $64 million over five years to encourage exploration of exceptionally innovative and original research ideas that have the potential for extraordinary impact.

4 Oct 2010

Blindness News and Research

AAO-MEACO Meeting highlights data on glaucoma risk in people with migraine, innovative uses of digital technology

Researchers report progress on two eye disease challenges at AAO-MEACO 2010 Joint Meeting

FDA approves BOTOX as prophylactic treatment for Chronic Migraine

New implantable pressure sensor for patients with cataract and glaucoma

Alimera Sciences obtains $32.5M senior secured credit facility

Issuing first report on NTDS, WHO aims for 'complete control' by 2015

Bayhill to present BHT-3009 Phase 2 clinical trial data at European Committee Congress

Bariatric surgery reduces healthcare costs for morbidly obese diabetics

Ocular Therapeutix completes Proof of Principle clinical study with moxifloxacin punctum plug

Alimera to present Iluvien Phase 3 clinical trial data at AAO annual meeting

Medicare recipients receiving treatment for retinal condition increases with shifts in procedure

Biologists recommend virtual institute for RNA research

Attorney Keith Jensen announces $3.78 million settlement with Pfizer on TEN case

Cell Cure, Teva Pharmaceutical enter license option agreement for OpRegen product

Scientists develop first screening method to identify river blindness disease

Depressed pregnant women at increased risk of delivering preterm birth and low-birth weight infants

Enzo commences clinical trial of Optiquel for chronic non-infectious uveitis

Cost-effective ways for early detection of 'lazy eye'

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

NIH to award $64M under Transformative Research Projects program

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News